ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	5.71	5.52	6.6	6.02	5.58	4.27
Research & Development	4.65	5	6.55	5.48	5.92	6.57
Other Operating Expenses	0.01	0	0	-0.04	0.01	-0.11
Operating Expenses	10.37	10.52	13.16	11.46	11.51	10.74
Operating Income	-10.37	-10.52	-13.16	-11.46	-11.51	-10.74
Other Expense / Income	-0.48	-0.46	0.02	-0.23	0.21	2.57
Pretax Income	-9.89	-10.06	-13.18	-11.23	-11.73	-13.31
Net Income	-9.89	-10.06	-13.18	-11.23	-11.73	-13.31
Preferred Dividends	0	0	0	0.12	0.4	4.22
Net Income Common	-9.89	-10.06	-13.18	-11.35	-12.12	-17.53
Shares Outstanding (Basic)	11	6	3	2	1	0
Shares Outstanding (Diluted)	11	6	3	2	1	0
Shares Change	240.94%	120.10%	41.31%	113.23%	155.90%	66.49%
EPS (Basic)	-1.14	-1.58	-4.56	-5.55	-12.60	-46.80
EPS (Diluted)	-1.14	-1.58	-4.56	-5.55	-12.60	-46.80
Free Cash Flow	-9.21	-9.57	-12.97	-11.17	-10.82	-8.63
Free Cash Flow Per Share	-0.85	-1.50	-4.49	-5.46	-11.28	-23.02
EBITDA	-9.63	-9.78	-12.94	-11.01	-11.56	-13.19
Depreciation & Amortization	0.26	0.28	0.23	0.22	0.17	0.12
EBIT	-9.89	-10.06	-13.18	-11.23	-11.73	-13.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).